07 August 2018
A leading treatment for cats with hyperthyroidism has won an industry award that recognises innovative products that encourage therapeutic compliance and improve feline welfare.
L-R: Becky Morris, Product Manager and Greg Williams, Senior Business Manager
Felimazole®, which is marketed by Dechra Veterinary Products, won the Easy to Give Award from the charity International Cat Care (ICC).
The ICC, whose veterinary arm is the International Society of Feline Medicine, makes the awards annually to a handful of products that are designed to make it particularly easy for owners to administer to cats, which minimise or reduce the number of times an owner has to administer medicines to the cat; or make dosing and or administration easier for owners.
Felimazole can be prescribed as part of a long-term treatment plan for cats with the endocrine disorder that affects thyroid production, particularly in older cats. Its active ingredient is thiamazole and it is available in 1.25 mg, 2.5 mg and 5 mg doses.
Dechra Brand Manager Claire Morgan said: “This award reflects the work that has gone into developing Felimazole as a long term, sustainable therapy for hyperthyroidism.
“It can be particularly difficult to administer regular medication to cats and it can become a stressful experience for both owner and pet so Felimazole’s small, smooth tablet design makes it ideal for regular dosing.
“Our research tells us that 91 per cent of owners have higher confidence in tablets to deliver the correct dose which makes Felimazole a perfect solution for this lifelong condition.”
Dechra also supports a dedicated website created to shed light on the endocrine condition for owners whose pets have been prescribed Felimazole as part of a long-term treatment plan.
www.feline-hyperthyroidism.co.uk has sections on symptoms, diagnosis, and treatment as well as useful do’s and don’ts and dietary information. Owners can also log on to their own interactive logbook to track their pet’s progress.
Felimazole® wins Easy to Give award